Why the Change? Inteliphage is evolving. We are no longer just a research-driven biotech – we are now fully committed to bringing next-generation bacteriophage therapies into routine clinical care for…
Read moreHow bacteriophages offer a promising natural solution for tackling superbugs and antimicrobial resistance and outlines the Belgian Vésale Bioscience company’s efforts to become a pioneer in the development of innovative,…
Read moreNamur (Belgium), 5 April 2023 Can phage therapy be a realistic alternative to fight antibiotic resistance in production animals? Join us on Wednesday, April 5, starting at 9:30 am at…
Read moreNamur (Belgium), 13 January 2023 Vésale Bioscience is developing innovative precision phage therapy solutions to treat bacterial infections resistant to antibiotics, and today announces that it has received a €1.8…
Read moreBiosaxony, the Saxony’s Biotechnology, Medical Technology & Health Economy Cluster in Leipzig, has selected Vésale Bioscience for their MEDICAL FORGE Accelerator program 2023 (
Read moreCMO Dr Vincent Grek joins Vésale Bioscience as Chief Medical Officer He has a Strong Clinical Development Expertise in the biotech, nutrition and pharmaceutical industry (antibiotics, gene therapy, enzyme replacement…
Read more
